Dongxing Zha

NAME: Dongxing Zha A. EDUCATION/TRAINING INSTITUTION AND LOCATION DEGREE(if applicable) YEAR(s) FIELD OF STUDY 1. Anhui Normal University, Wuhu, China B.Sc. 1987-1991 Biology 2. Huazhong Agricultural University, Wuhan, China Ph.D. 1991-1996 Molecular Biology 3. Chinese Academy of Science, Shanghai, China Postdoctoral 1997-1998 Human genomics 4. Max-Planck Institute, Mülheim an der Ruhr, Germany Postdoctoral 1999-2002 Directed Evolution B Positions and Honors. 1997-1998, Postdoctoral Fellow, Max-Planck Guest Laboratory, CAS, Shanghai, China 1998-1999, Research Scientist, Novo Nordisk (China), Beijing, China 1999-2002, Postdoctoral Fellow, Max-Planck-Institut für Kohlenforschung, Mülheim, Germany 2002-2005, Scientist II, GlycoFi,Inc., Lebanon, NH 2002-2006, Senior Scientist, GlycoFi, Inc., Lebanon, NH 2006-2008, Research Fellow, Merck & co. Inc, Lebanon, NH 2008-2014, Group Leader, antibody Discovery, Merck Research Laboratory 2014-2017, Institute Group Leader, MD Anderson Cancer Center, Houston, TX 2017-2018, Institute Associate Director, ORBIT, MD Anderson, Houston, TX 2018-2021, Institute Head, ORBIT Platform, MD Anderson, Houston, TX 2021-Present, CTO at Alloy Therapeutics, Founder and CEO at KeywayTM TCR Discovery 2022-Present, Founder and CEO, Ypsilon Therapeutics Selected publications: 1: Leukemia. 2025 Aug;39(8):1948-1959. doi: 10.1038/s41375-025-02652-0. 2: Leukemia. 2025 Apr;39(4):888-898. doi: 10.1038/s41375-025-02520-x. 3: Cancers (Basel). 2024 Nov8;16(22):3776. 4: Leukemia. 2023 Oct;37(10):2006-2016. 5: Front Immunol. 2019 Jan 18;9:3153.